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Total expenditure for adult critical care in England, Wales and 
Northern Ireland in 2008/2009 amounted to £1 billion1, 
approximately 1% of the total National Health Service (NHS) 
Budget. Spending on health in the UK represents 
approximately 9% of Gross Domestic Product (GDP), which is 
comparable with other Organisation for Economic 
Cooperation and Development (OECD) countries2. However, 
there is a well-recognised, wide variation in spending on 
critical care internationally not fully explained by differences in 
epidemiology of critical illness or variations in the definition of 
critical care, though the latter makes direct comparisons of the 
funding and organisation of critical care between countries 
problematic. Such variations are also independent of national 
GDP and proportion of GDP allocated to health. 
Although critical care is a high-cost, low-volume specialty1, 
especially relative to preventative or primary care 
interventions, there is evidence that critical care provision in 
the UK NHS can be very cost-effective3,4.  
Acting in individual patients’ best interests when presenting to 
critical care is the central tenet of clinical practice. Yet 
healthcare delivery in all settings occurs in the context of finite 
resources and ever-increasing demand, making it a scarce 
resource. Drivers for rising demand5 in critical care include: 
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 an ageing population living longer with multiple long-
term conditions 
 increasing number and complexity of surgical 
interventions performed 
 development of new therapies 
 rising public expectations of the availability and 
effectiveness of healthcare based in improved 
outcomes over time. An observational study in 
Australia and New Zealand6 showed in-hospital 
mortality secondary to severe sepsis and septic shock 
decreased year on year between 2000 and 2012 from 
35% to 18.4%, unrelated to changes in case definitions 
or illness severity.  
B: Scarcity and rationing 
The relative scarcity of healthcare necessitates alignment of 
individual patient interests with sustainable models of 
providing healthcare. The NHS Commissioning Board7 (NHSCB) 
acknowledges that it ‘does not have the budget to fulfil all 
needs of all patients within its area of responsibility’. The US 
Task Force on Values, Ethics and Rationing in Critical Care8 
defines rationing as ‘the allocation of healthcare resources in 
the face of limited availability, which necessarily means that 
beneficial interventions are withheld from some individuals’.  
Rationing within healthcare occurs at three levels9:  
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 Macro-level rationing at state or national government 
level when determining overall health budgets, with 
governments being accountable to their electorates. 
 Meso-level rationing regionally or locally e.g. Clinical 
Commissioning Groups (CCGs) that are accountable to 
the Secretary of State for Health via NHS England, 
assessed broadly by their population health outcomes 
and spending. 
 Micro-level rationing, also referred to as bedside 
rationing, occurs at the level of individual clinicians and 
patients.  The General Medical Council’s (GMC) 
leadership and management guidance10 states all 
doctors should be prepared to contribute to 
discussions about resource allocation, priority setting 
and commissioning of services for the wider patient 
population. Decisions affecting patients should be ‘fair, 
based on clinical need and the likely effectiveness of 
treatments’, acknowledging that ‘treatment options 
that can be offered to patients may be affected by 
limits in resources’.  
B: Who should have access to critical care? 
There are various approaches to determining who needs 
access to healthcare11. Clinical need is often defined in terms 
of capacity to benefit from available therapies. This is in 
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keeping with the GMC’s leadership guidance9 and the NHSCB 
definition6 of a healthcare need as a health problem that ‘can 
be addressed by a clinically effective intervention’. Conversely, 
denying patients access to interventions where there is little or 
no expected health benefit is not rationing11.  
In critical care, cost-effectiveness of admission is also related 
to capacity to benefit. The most critically-ill patients have the 
most to gain (in terms of mortality reduction) from 
admission12. As many costs of ICU are fixed irrespective of 
illness severity, the cost-effectiveness of admitting patients 
with higher predicted mortality improves in comparison to 
those with lower predicted mortality. A multicentre 
prospective observational study12 (Table 1) showed that the 
effectiveness (relative risk reductions in 28-day mortality) for 
patients admitted to ICU compared with non-admitted 
referrals varied with predicted mortality. Similarly, the cost-
effectiveness of ICU admission (cost per life saved and cost per 
life-year saved) was greatest for patients with predicted 
mortality ≥ 40%. 
The strategic aims of NHS England regarding provision of 
critical care 13 are to: 
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 Prevent avoidable mortality and morbidity due to 
patients requiring critical care not accessing the 
appropriate level of care or organ support. 
 Avoid triage by resource as opposed to triage by 
outcome. Patients should have access to care based on 
anticipated capacity to benefit from treatment rather 
than on what facilities are available (namely availability 
of staffed ICU beds).  
 Achieve equity of access to treatment. Patients with 
equivalent clinical need (in terms of severity of illness 
and capacity to benefit) should have equal access to 
optimal care irrespective of, for example, location or 
time of presentation. 
B: Value, cost-effectiveness and efficiency in critical care 
Value for money in healthcare can be defined as achieving 
best health outcomes relative to cost14. The objective of health 
economics is to maximise the value obtained from a given set 
of resources by prioritising interventions delivering greatest 
health benefits for cost. Cost- effectiveness is synonymous 
with value for money although it tends to imply value for 
money determined by means of a cost-effectiveness analysis 
(CEA).  
Measurement of value for money in critical care includes the 
use of the Intensive Care National Audit and Research Centre 
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Case Mix Programme15 (ICNARC CMP) to aid ‘decision-making, 
resource allocation and local quality improvement.’  
There are two types of efficiency in health economics9. First, 
allocative efficiency is concerned with ensuring that the value 
derived from a service outweighs the costs of its production. 
The greater the value relative to cost, the more allocatively 
efficient the service.  The second type of efficiency is technical 
efficiency, which is concerned with maximising the outcomes 
available with a given level of resources. The more outcomes 
that can be produced for a given budget, the more technically 
efficient the service.  
Questions around what the best proportion of healthcare 
spending that should be allocated to critical care is (budget 
setting), and which groups of patients should have access to 
critical care (case selection) address allocative efficiency. 
Technical efficiency considers how a given budget can best be 
used to maximise delivery or minimise cost of a service. 
Clinical governance and quality improvement projects in 
critical care largely focus on the technical efficiency of service 
provision through improving processes and cost-containment 
at a local or regional level. Critical care admission practices 
could affect both local allocative efficiency and technical 
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efficiency. It is possible for a service to be technically efficient 
while being allocatively inefficient. 
B: Economic evaluation in critical care 
Economic evaluations in critical care can provide evidence to 
improve efficiency of resource allocation16.  Comparisons 
between interventions within critical care can be made to 
prioritise how resources are best utilised within the specialty, 
as well as against very different uses of scarce healthcare 
resources. The main types of health economic evaluation9, 16,17 
are: 
 Cost-benefit analysis (CBA): Total costs and total 
benefits of interventions (measured purely in monetary 
terms) are compared. This requires a monetary value 
to be assigned to all outcomes. For example, if 
comparing methods of weaning sedation and 
ventilatory support, a monetary cost would need to be 
assigned to outcomes such as an episode of delirium or 
pain and distress experienced by patients. CBA has the 
advantage of being able to assess allocative efficiency 
but the information requirements are onerous and 
monetising health outcomes can be viewed as morally 
objectionable.  
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 Cost-minimisation analysis (CMA): In circumstances 
where the effects of the interventions are 
therapeutically identical, the objective is to identify the 
lowest cost option. That is, outcomes including side-
effect profiles and duration of treatment between 
compared interventions are equivalent. Such 
evaluations have been used to compare drug 
treatments but it is rare for therapies to have identical 
outcomes so their role is increasingly narrow. 
 Cost-effectiveness analysis (CEA): An economic 
evaluation whose outcome measure is one of 
incremental cost-effectiveness i.e. the difference in 
cost between two interventions divided by the 
difference in their effect. This involves estimating or 
measuring the total costs of an intervention against the 
health benefits measured in natural units such as 
premature deaths avoided, cases prevented or changes 
in measures such as ICU or hospital length of stay. 
Table 1 shows some examples of CEA s within critical 
care. CEA is relatively straightforward but can only be 
used to compare interventions with the same outcome 
measures e.g. 28-day mortality. Cost effectiveness is 
expressed in terms of the additional cost per unit of 
effect, such as cost per life saved. This is also known as 
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the Incremental Cost Effectiveness Ratio (ICER). The 
denominator, difference in effect between intervention 
and control, is equivalent to the Absolute Risk 
Reduction (ARR) between groups.  
𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑅𝑎𝑡𝑖𝑜  =
𝐶𝑜𝑠𝑡𝑠 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛−𝐶𝑜𝑠𝑡𝑠 𝑜𝑓𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝐸𝑓𝑓𝑒𝑐𝑡 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛−𝐸𝑓𝑓𝑒𝑐𝑡 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐴𝑅𝑅)
 
 Cost-utility analysis (CUA): This is a special case of 
cost-effectiveness analysis where the effects are 
measured in terms of a utility (a measure of preference 
or value that an individual or society assigns a health 
state). The most widely used utility measure is the 
Quality Adjusted Life Year (QALY). By standardising the 
outcome measure, CUAs allow direct comparison of 
very different health interventions with different 
health benefits. This facilitates explicit resource 
allocation decisions such as those made by the UK 
National Institute for Health and Care Excellence 
(NICE), where treatments under £20,000 per QALY 
gained are generally considered cost-effective and 
those above £30,0003.4 per QALY are less frequently 
approved.  
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C: QALYs and measuring health utility 
QALYs are a composite measure of the state of health of a 
person or group in which benefits, in terms of length of life, 
are adjusted to reflect the quality of life. Using QALYs as a 
composite outcome measure allows morbidity and mortality 
to be considered together18,19. QALYs are calculated by 
weighting each expected year of life by the quality, or utility, 
of that year on a scale of 0 (dead) to 1 (perfect health). For 
example, 1 year of life in perfect health would count as 1.0 
QALYs, whilst one year at 60% of full health would count as 0.6 
QALYs. For health states seen as worse than death, a negative 
utility value can be assigned. 
A US study of predictors of health utilities in Acute Respiratory 
Distress Syndrome (ARDS) survivors using the Euro Quality of 
Life 5 Dimension (EQ-5D) Health Related Quality of Life 
(HRQoL) questionnaire, reporting extreme problems in all five 
domains corresponded with a calculated health utility of -0.11 
compared with utility of 1.0 with no problems in any of 
domains21.   
Health state utilities can be elicited directly, using techniques 
such as the standard gamble (SG) or time trade-off (TTO), or 
indirectly (Figure 1), using generic HRQoL questionnaires such 
as the Short Form (36) Health Survey (SF-36) or EQ 5D.  With 
direct approaches individuals are asked to rate their health 
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across a series of dimensions.  These ratings are assigned 
utility scores derived using TTO methods in a different sample 
of the general population.  Indirect methods are more 
straightforward to administer and are much more common in 
health economic evaluations than direct methods, but it is 
important to recognise the potential for divergence between 
the preferences of the patients rating the health states and 
the public sample involved in eliciting the utility weights. Such 
differences have implications for the estimation of QALYs and 
cost-effectiveness of interventions. 
In the same way that clinical evidence needs to be critically 
appraised to understand how transferable the evidence is to a 
local population or case-mix, health economic evaluations also 
need to be understood in a local context8,12,16 and are perhaps 
even more context-sensitive as costs vary greatly between 
health systems and over time18.  
One cost that should ideally be included in estimates of total 
costs of interventions or models of care is opportunity cost 9,21.  
When choices are made regarding how best to use scarce 
resources, there is always a next-best alternative that cannot 
be chosen. This is the opportunity cost: the value of the best, 
mutually exclusive alternative foregone to pursue a certain 
action. For example, in critical care, part of the total cost of 
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buying specific equipment or funding interventions is the value 
that could otherwise be gained by the next-best use of the 
same resources, either within critical care or a different 
treatment area. Similarly, the impact of micro-level resource 
allocation decisions that lead to an ICU operating at full 
capacity (even when such decision-making is optimal) occurs 
at the cost of being able to admit new referrals in a timely 
manner, with potentially harmful consequences21,22.  
C: Challenges in measuring cost-effectiveness 
Maximising the value14 of critical care by improving clinical 
outcomes is key to efficient resource allocation. If acting in 
patients’ best interests is at the heart of good practice, then 
the outcomes measured need to be of importance and 
relevance to patients. Outcomes measured in much critical 
care research have often focused on short-term mortality (at 
best), changes in physiological parameters or process 
measures (such as length of stay) used as proxies for improved 
clinical outcomes. As short-term mortality has improved, so 
research is increasingly aimed at longer-term mortality, 
morbidity, HRQoL23 and socio-economic impact of critical 
illness on patients24 and carers. 
Apart from the practical difficulties in measuring longer-term 
patient-centred outcomes, critical care outcomes research 
faces many challenges. First, the heterogeneity of the patient 
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population within critical care, both in terms of the pre-
existing health status of patients and the diversity of critical 
illness presentations such as sepsis, trauma and respiratory 
failure. Second, outcomes in critical care are heavily 
dependent on performance in many other clinical areas such 
as the Emergency Department, operating theatres, pre-
hospital and diagnostic services. Therefore, measuring 
outcomes directly attributable solely to critical care is difficult. 
Third, outcomes research attempting to predict patient 
outcome, such as illness severity scoring systems, provide 
estimates of outcome probability at a population level which 
are not transferable to individual patients. 
Similarly, measuring costs of critical care are equally 
challenging. Current measures focus largely on generating an 
average daily cost for critical care multiplied by length of 
patient stay to give an estimate of cost for length of ICU stay. 
First, as with outcomes, costs of critical care are heavily 
dependent on areas outside the critical care unit. Second, cost 
of critical care is not constant throughout patient stay1. Patient 
stay tends to be particularly resource intensive early in the ICU 
admission and less so as length of stay increases. Third, the 
heterogeneous case-mix means patient costs can be very 
variable. Fourth, despite difficulties in accurate measurement 
of short-term ICU costs, an idea of resource utilisation by 
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survivors of ICU in the community is needed to estimate the 
true cost-effectiveness of providing critical care.  
C: Appraising CEAs in critical care 
The reliability of any CEA is only as good as the quality of the 
data it is based on. For an intervention to be cost-effective, it 
must first be shown to be clinically effective. The more robust 
the clinical effectiveness data, the less uncertainty surrounds 
the cost-effectiveness estimates. Defining effective critical 
care interventions as those which lead to improved survival 
and health of those exposed to critical illness requires 
evidence of meaningful improvements in patient-centred 
outcomes, namely sustained reductions in mortality with 
satisfactory functional recovery and HRQoL. The short-term 
outcome measures most commonly used in ICU studies are 
not well suited to robust CEAs. 
In addition, the costs and effects considered depend on the 
perspective chosen for the valuation and this needs to be 
stated in any health economic analysis. This could be at the 
level of an individual ICU, hospital, national health system or a 
societal perspective. The latter is preferred because it is the 
broadest perspective, considering all costs and benefits, 
including those incurred in sectors outside health and the 
impact of interventions on caregivers. NICE guidelines, 
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however, currently recommend a payer perspective as it is 
more relevant to funding decisions. In the NHS, this would be 
the commissioning board or the local CCG. With the drive 
toward integration of health and social care, a societal 
perspective may be increasingly needed to compare different 
interventions or models of care.   
A systematic review of CEAs in critical care16 found that 2 of 14 
studies assessed, used a societal perspective in evaluating 
cost-effectiveness. These were both assessing the economic 
impact of activated protein C in sepsis, a treatment where 
considerable prospective cost-effectiveness data was 
published. Though this evidence is now largely obsolete since 
the drug was withdrawn due to doubts around the evidence of 
its clinical effectiveness and safety, the methodology is still 
noteworthy. 
Sensitivity analysis is a technique used in economic 
evaluations to vary the underlying assumptions of costs or 
effects used in the analysis and around which there is 
uncertainty. It allows multiple ‘what if?’ scenarios to be 
performed16, testing the robustness of the conclusions and is 
recommended when conducting CEAs. 
Discounting25 is performed to account for ‘time preference’. 
This is the idea that people weight costs and benefits that 
17 
 
occur now more strongly than costs and benefits that will 
occur in the future. For example, most individuals would 
prefer to receive £100 today to £100 a year from today. 
Similarly, a QALY gained in the present is valued more highly 
than one in the future. The discount rate represents the 
degree to which future events are less heavily weighted, or 
discounted. 3.5% is the discount rate recommended and used 
by NICE. 
Analysing the cost-effectiveness of specific interventions 
within critical care from the perspective of the individual unit 
or hospital trust may sometimes be sufficient to guide 
resource allocation decisions. Minimising costs at the level of a 
hospital trust or individual unit is important, provided the 
effectiveness of care is not compromised. However, cost 
minimisation within critical care may simply serve to displace 
costs to a different part of the health service or the 
community. While this may benefit fiscal management within 
a hospital trust or directorate, it merely represents cost-
shifting as there is no gain in overall efficiency or cost-
effectiveness of the system. 
B: Conclusion 
The excess demand for healthcare relative to supply means 
not all beneficial health interventions can be funded. Rationing 
is, therefore, an unavoidable feature of health systems.  
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There is evidence that critical care can be a very cost-effective 
use of healthcare resources compared with other 
interventions. However, demand for critical care is continually 
rising. As short-term survival following intensive care 
continues to improve, measuring longer-term patient-centred 
outcomes is increasingly important to guide resource 
allocation decisions. Estimating both the direct and indirect 
costs of critical care provision to the health system, patients, 
carers and wider society need to be included in health 
economic evaluations of critical care. Although significant 
challenges exist in measurement of both outcomes and costs, 
doing so would produce increased understanding of how to 
sustainably deliver valuable critical care. 
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